EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Applied Therapeutics's Enterprise Value is $47.39 Mil.
Applied Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-81.84 Mil. Therefore, Applied Therapeutics's EV-to-FCF for today is -0.58.
The historical rank and industry rank for Applied Therapeutics's EV-to-FCF or its related term are showing as below:
APLT'
s EV-to-FCF Range Over the Past 10 Years
Min: -16.61 Med: -4.62 Max: -0.4
Current: -0.58
During the past 7 years, the highest EV-to-FCF of Applied Therapeutics was -0.40. The lowest was -16.61. And the median was -4.62.
APLT's EV-to-FCF is ranked worse than 100% of 385
companies
in the Biotechnology industry
Industry Median: 8.82
vs APLT: -0.58
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Applied Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Applied Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Applied Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Applied Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Applied Therapeutics's EV-to-FCF falls into.
Applied Therapeutics's current Enterprise Value is $47.39 Mil.
Applied Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Applied Therapeutics's PE Ratio (TTM) for today is calculated as:
Applied Therapeutics's share price for today is $1.14.
Applied Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.610.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Applied Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Applied Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APLT has been successfully added to your 